news

Oxular appoints Dr. Friedrich Asmus as CMO

Dr. Asmus brings two decades of experience leading global clinical and translational research programs for both retinal and rare diseases. OXFORD, UK, 7 June 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces it has appointed Dr. Friedrich (Fritz) Asmus as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, …

Oxular appoints Dr. Friedrich Asmus as CMO Read More »

Oxular raises $37 million

Led by specialist life sciences investor, Forbion Investment will fund Phase 2 human clinical studies evaluating Oxular’s 12-month treatment for diabetic macular edema, and accelerate development of early-product pipeline OXFORD, UK, 1 March 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announced that it has completed a $37 million (£27 million) financing …

Oxular raises $37 million Read More »

Dr. Jatinder Kapur appointed as VP of Quality

Appointment builds Oxular’s team as it prepares to enter human clinical studies evaluating OXU-001 OXFORD, UK, 8 February 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces that it has appointed Dr. Jatinder Kapur as Vice President of Quality. His primary responsibilities include establishing and managing the Company’s Quality Management System, …

Dr. Jatinder Kapur appointed as VP of Quality Read More »

Retinoblastoma treatment receives Rare Paediatric Disease and Orphan-Drug Designations

Provides furthered momentum for OXU-003 development programme OXFORD, England, Oct. 12, 2020 Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces it has received both Rare Paediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (U.S. FDA) for OXU-003, the Company’s proprietary drug in development for the treatment of retinoblastoma. …

Retinoblastoma treatment receives Rare Paediatric Disease and Orphan-Drug Designations Read More »

Dr. Rafiq Hasan appointed as Non-Executive Director

Oxular Limited Appoints Dr. Rafiq Hasan as Non-Executive Director OXFORD, UK, 5 October 2020 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces it has appointed Dr. Rafiq Hasan as a Non-Executive Director of the Company. Dr. Hasan gained his medical degree in London and has pursued a highly successful career in …

Dr. Rafiq Hasan appointed as Non-Executive Director Read More »

OBN Awards 2016 –Winners Recognised at Industry Leading Event

Abingdon, UK, 7 October 2016 – OBN Ltd, the membership organisation supporting the UK’s innovative life sciences companies, are delighted to announce the winners of the prestigious OBN Awards 2016 that were presented last night in front of a sold-out audience of over 250 leaders from Biotech, Medtech and Investment companies at the Town Hall …

OBN Awards 2016 –Winners Recognised at Industry Leading Event Read More »

£15.5m Series A financing complete

V-Bio Ventures joins investment syndicate Completes oversubscribed £15.5 million Series A financing round Accelerates development of additional product candidates Investors include Imperial Innovations, Consort Medical plc, NeoMed, V-Bio Ventures and Hovione Scientia Ltd Tuesday, 19 July 2016 – Precision Ocular, the Oxford-based retinal therapeutics company, today announces that V-Bio Ventures joins the Company’s successful Series …

£15.5m Series A financing complete Read More »

Innovations leads £13.5m funding round in Precision Ocular

22 February 2016 – Imperial Innovations Group plc (AIM: IVO, ‘the Group’, ‘Innovations’) has led a £13.5 million investment round in Precision Ocular Ltd (Precision Ocular), a London-based retinal therapeutics company. Innovations has committed £6.9 million to the round alongside other investors, including Consort Medical plc, a leading global single source pharma services drug and …

Innovations leads £13.5m funding round in Precision Ocular Read More »

Scroll to Top